223 related articles for article (PubMed ID: 22224483)
21. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
[TBL] [Abstract][Full Text] [Related]
22. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
Charalabidis A; Sfouni M; Bergström C; Macheras P
Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of DILI Predictive Hypotheses in Early Drug Development.
Chan R; Benet LZ
Chem Res Toxicol; 2017 Apr; 30(4):1017-1029. PubMed ID: 28257576
[TBL] [Abstract][Full Text] [Related]
24. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery.
Larregieu CA; Benet LZ
Mol Pharm; 2014 Apr; 11(4):1335-44. PubMed ID: 24628254
[TBL] [Abstract][Full Text] [Related]
25. Predicting Passive Permeability of Drug-like Molecules from Chemical Structure: Where Are We?
Broccatelli F; Salphati L; Plise E; Cheong J; Gobbi A; Lee ML; Aliagas I
Mol Pharm; 2016 Dec; 13(12):4199-4208. PubMed ID: 27806577
[TBL] [Abstract][Full Text] [Related]
26. Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.
Camenisch GP
Pharm Res; 2016 Nov; 33(11):2583-93. PubMed ID: 27439505
[TBL] [Abstract][Full Text] [Related]
27. Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems.
Idkaidek NM
Saudi Pharm J; 2014 Jan; 22(1):79-81. PubMed ID: 24493977
[TBL] [Abstract][Full Text] [Related]
28. Generative topographic mapping-based classification models and their applicability domain: application to the biopharmaceutics Drug Disposition Classification System (BDDCS).
Gaspar HA; Marcou G; Horvath D; Arault A; Lozano S; Vayer P; Varnek A
J Chem Inf Model; 2013 Dec; 53(12):3318-25. PubMed ID: 24320683
[TBL] [Abstract][Full Text] [Related]
29. Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System.
Bowman CM; Benet LZ
Drug Metab Dispos; 2016 Nov; 44(11):1731-1735. PubMed ID: 27519549
[TBL] [Abstract][Full Text] [Related]
30. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
[TBL] [Abstract][Full Text] [Related]
31. Intestinal drug transporters: an overview.
Estudante M; Morais JG; Soveral G; Benet LZ
Adv Drug Deliv Rev; 2013 Oct; 65(10):1340-56. PubMed ID: 23041352
[TBL] [Abstract][Full Text] [Related]
32. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the interplay of physiological response to food intake and drug properties in food-drug interactions.
Sharma S; Kogan C; Varma MVS; Prasad B
Drug Metab Pharmacokinet; 2023 Dec; 53():100518. PubMed ID: 37856928
[TBL] [Abstract][Full Text] [Related]
34. The use of drug metabolism for prediction of intestinal permeability (dagger).
Chen ML; Yu L
Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
[TBL] [Abstract][Full Text] [Related]
35. Predicting when biliary excretion of parent drug is a major route of elimination in humans.
Hosey CM; Broccatelli F; Benet LZ
AAPS J; 2014 Sep; 16(5):1085-96. PubMed ID: 25004821
[TBL] [Abstract][Full Text] [Related]
36. Computational-Regulatory Developments in the Prediction of Oral Drug Absorption.
Valsami G; Macheras P
Mol Inform; 2011 Mar; 30(2-3):112-21. PubMed ID: 27466762
[TBL] [Abstract][Full Text] [Related]
37. Targeting intestinal transporters for optimizing oral drug absorption.
Varma MV; Ambler CM; Ullah M; Rotter CJ; Sun H; Litchfield J; Fenner KS; El-Kattan AF
Curr Drug Metab; 2010 Nov; 11(9):730-42. PubMed ID: 21189135
[TBL] [Abstract][Full Text] [Related]
38. Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions.
Hosey CM; Benet LZ
Mol Pharm; 2015 May; 12(5):1456-66. PubMed ID: 25816851
[TBL] [Abstract][Full Text] [Related]
39. Application of data mining approach to identify drug subclasses based on solubility and permeability.
Gatarić B; Parojčić J
Biopharm Drug Dispos; 2019 Feb; 40(2):51-61. PubMed ID: 30635908
[TBL] [Abstract][Full Text] [Related]
40. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.
Dahan A; Miller JM; Amidon GL
AAPS J; 2009 Dec; 11(4):740-6. PubMed ID: 19876745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
